| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Misonidazole has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-yl]oxyoxane-2-carboxylic acid. |
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Data
Rat(po): LD50: 2131 mg/kg Mouse(po): LD50: 1869 mg/kg Mouse(ip): LD50: 1340 mg/kg Mouse(sc): LD50: 1414 mg/kg |
| Additional Infomation |
Misonidazole is an organic molecular entity.
Misonidazole is under investigation in clinical trial NCT00038038 (Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole). Misonidazole is a nitroimidazole with radiosensitizing and antineoplastic properties. Exhibiting high electron affinity, misonidazole induces the formation of free radicals and depletes radioprotective thiols, thereby sensitizing hypoxic cells to the cytotoxic effects of ionizing radiation. This single-strand breaks in DNA induced by this agent result in the inhibition of DNA synthesis. (NCI04) A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic. |
| Molecular Formula |
C7H11N3O4
|
|---|---|
| Molecular Weight |
201.182
|
| Exact Mass |
201.074
|
| CAS # |
13551-87-6
|
| PubChem CID |
26105
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
438.5±55.0 °C at 760 mmHg
|
| Flash Point |
219.0±31.5 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
-0.28
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
196
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COCC(CN1C=CN=C1[N+](=O)[O-])O
|
| InChi Key |
OBBCSXFCDPPXOL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H11N3O4/c1-14-5-6(11)4-9-3-2-8-7(9)10(12)13/h2-3,6,11H,4-5H2,1H3
|
| Chemical Name |
1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol
|
| Synonyms |
Misonidazole NSC-261,037 NSC 261037 SR 1354 SRI 1354 Ro 7-0582
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9707 mL | 24.8534 mL | 49.7067 mL | |
| 5 mM | 0.9941 mL | 4.9707 mL | 9.9413 mL | |
| 10 mM | 0.4971 mL | 2.4853 mL | 4.9707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00606294 | COMPLETEDWITH RESULTS | Radiation: fluorine-18-labeled fluoro-misonidazole (18F-FMISO) Device: 18F-FMISO PET scan Device: MRI Device: FDG PET/CT scan |
Head and Neck Cancer | Memorial Sloan Kettering Cancer Center | 2004-06 | Not Applicable |
| NCT06205927 | RECRUITING | Radiation: Standard carbon ion beam radiotherapy Radiation: Carbon ion beam radiotherapy simultaneously dose boost |
Non-small Cell Lung Cancer | Jian Chen | 2023-10-12 | Phase 2 |
| NCT00574353 | WITHDRAWN | Radiation: Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission |
Colorectal Cancer | Memorial Sloan Kettering Cancer Center | 2007-12 | Not Applicable |
| NCT01898065 | COMPLETED | Drug: 18-F-MISO | Prostate Adenocarcinoma | Institut Cancerologie de l'Ouest | 2012-06 | Phase 2 |
| NCT01868906 | TERMINATED | Drug: 18F-FMISO Procedure: PET without SCS Device: SCS |
Malignant Glioma | Bernardino Clavo, MD, PhD | 2013-06 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
